• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delcath to settle shareholder suits for $8.5m

July 8, 2015 By Fink Densford

Delcath to settle shareholder suits for $8.5mDelcath (NSDQ:DCTH) said yesterday that it agreed to pay $8.5 million to settle a clutch of lawsuits filed by shareholders over losses related to its development of the drug-device combination Melblez kit.

The lawsuits, filed by shareholders in 2013, sought compensation for losses between April 21, 2010, and May 2, 2013, stemming from 3 separate incidents the plaintiffs claim caused share prices to drop significantly.

The plaintiffs claimed Delcath made false or misleading statements about its development of Melblez, withholding information about severe toxicity and deaths associated with adverse reactions, as well as facility violations of current good manufacturing practices. DCTH shares dropped 96%, from $11.30 per share in 2011 to an eventual price of 46¢ apiece in 2013. The stock was trading at 87¢ per share in mid-afternoon activity today, down -4.4% on the day.

Investors back then were reacting to Delcath’s failed attempt to win an New Drug Application for Melblez, after the FDA found issues with their manufacturing process, a high rate of death during testing and the risks of the drug outweighing the benefits, according to the suits.

Delcath said it agreed to a proposed settlement fund of $8.5 million in return for for the release of all claims in the litigation. The final approval hearing for the case is scheduled for October 19.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Delcath Systems Inc.

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS